 |
|
|
| |
PERCEPTIONS OF AND PREFERENCES FOR ORAL OR LONG-ACTING INJECTABLE ANTIRETROVIRAL TREATMENT REGIMENS IN THE UNITED STATES AND CANADA
|
| |
| |
Reported by Jules Levin
IDWeek 2019™; October 2-6, 2019; Washington, DC, USA
CP. Garris1, S. Heidenreich2 ,E. Arthurs3, K. Cutts4, FA. Spinelli1, H. Collacott2, E. Lowman5, H. Rice6, B. Lebouche7, GN. Chua2, H. Gelhorn4
1ViiV Healthcare, RTP, NC, US;2Evidera, London, UK; 3GlaxoSmithKline, Mississauga, ON, Canada; 4Evidera, Bethesda, MD, US; 5Midland Medical Center, Oakland Park, FL, US; 6Rice Medical Group, Mountain View, CA, US; 7Centre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
from Jules: current adherence issues, food restrictions, side effects were important to patients - to physicians side effects & adherence were issues
|
| |
|
|
|
|
|
